Cilta-Cel Treatment Safe, Effective for Relapsed/Refractory …
Oct 8, 2024 · By Lori Solomon HealthDay Reporter. TUESDAY, Oct. 8, 2024 -- Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according to a study published online Oct. 4 in Blood. Surbhi Sidana, M.D., from Stanford University in California, and colleagues reported ...
ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
WEDNESDAY, Dec. 13, 2023 -- For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd) improves progression-free survival.
Multiple Myeloma - What You Need to Know - Drugs.com
Nov 3, 2024 · Alcohol can thin your blood and make it easier to bleed. Drink liquids as directed. You may need to drink extra liquids to prevent dehydration. Ask how much liquid to drink each day and which liquids are best for you. Exercise regularly. Multiple myeloma or its treatment may make you feel tired. Exercise can help you have more energy.
Can Venclexta be used for Multiple Myeloma? - Drugs.com
Last updated on Aug 8, 2024. Although Venclexta is not FDA approved for use in Multiple Myeloma (MM), some research indicates that it may be promising for some MM patients who have failed at least one prior treatment, especially those with the genetic abnormality t (11;14) or with high levels of BCL-2. However, its use is not without controversy.
FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma
Apr 9, 2024 · The approval is for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma is a one-time infusion, with a new recommended dose range of 300 to 510 x 10 6 CAR-positive T cells ...
Multiple Myeloma News & Updates - Drugs.com
Aug 8, 2024 · Darzalex Faspro (daratumumab and hyaluronidase-fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible HORSHAM, Pa., July 30, 2024 – Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and ...
List of 59 Multiple Myeloma Medications Compared - Drugs.com
Multiple myeloma is a type of cancer that forms in plasma cells (also called mature B-lymphocytes), which are a type of white blood cell that is made in the bone marrow. Multiple myeloma treatments aim to manage symptoms, slow disease progression, and improve quality of life. They typically involve a combination of therapies, such as:
Velcade (bortezomib): Uses, Dosage & Side Effects - Drugs.com
Velcade (bortezomib) is used to treat multiple myeloma (MM) and mantle cell lymphoma (MCL) in adults. Velcade injection is a proteasome inhibitor, a type of targeted cancer drug. Velcade injection is not chemotherapy. Velcade works by blocking enzymes (proteasomes), which usually break down proteins inside cancer cells.
Triplet Therapy Including Belamaf Prolongs Survival in Multiple …
FRIDAY, Feb. 9, 2024 -- For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an acceptable safety profile, according to a study presented during the February 2024 session of the American Society for Clinical Oncology ...
Carfilzomib: Uses, Dosage, Side Effects, Warnings - Drugs.com
Apr 4, 2023 · People with multiple myeloma have abnormal plasma cells, which are a type of white blood cell found in your bone marrow that secrete antibodies (immunoglobulins). These antibodies are protective proteins that help fight infection. When plasma cells become cancerous they grow out of control and make an abnormal antibody. Carfilzomib works by ...